Knights of Columbus Asset Advisors’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-25,985
Closed -$230K 365
2022
Q4
$230K Sell
25,985
-510
-2% -$5.6K 0.02% 287
2022
Q3
$324K Buy
26,495
+3,277
+14% +$51.1K 0.03% 256
2022
Q2
$275K Hold
23,218
0.03% 263
2022
Q1
$442K Buy
23,218
+235
+1% +$4.37K 0.04% 253
2021
Q4
$610K Buy
22,983
+423
+2% +$14.6K 0.05% 243
2021
Q3
$927K Sell
22,560
-22,501
-50% -$1.23M 0.08% 226
2021
Q2
$2.55M Buy
45,061
+17,132
+61% +$633K 0.24% 141
2021
Q1
$1.17M Buy
27,929
+4,925
+21% +$281K 0.11% 237
2020
Q4
$1.61M Sell
23,004
-11,702
-34% -$481K 0.17% 212
2020
Q3
$974K Sell
34,706
-5,108
-13% -$166K 0.12% 237
2020
Q2
$1.18M Buy
39,814
+37,049
+1,340% +$968K 0.14% 225
2020
Q1
$55K Sell
2,765
-597
-18% -$15.1K 0.01% 356
2019
Q4
$100K Buy
+3,362
New +$84K 0.01% 372

Other funds holding EDIT

Knights of Columbus Asset Advisors's EDIT Position: Q1 2023 in Review

Knights of Columbus Asset Advisors sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 25,985 shares — an estimated $230K sold.

Knights of Columbus Asset Advisors first reported a position in EDIT in Q4 2019 and held it in 13 quarters. The position peaked at $2.55M in Q2 2021. 235 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

  • Knights of Columbus Asset Advisors reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 25,985 Editas Medicine shares in Q1 2023, an estimated $230K.
  • Knights of Columbus Asset Advisors first reported a position in Editas Medicine in Q4 2019 and held it in 13 quarters.
  • Knights of Columbus Asset Advisors's Editas Medicine position peaked at $2.55M in Q2 2021.
  • 235 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2023, filed 1 May 2023.